Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immediate versus deferred switch to ritonavir-boosted darunavir in HIV-infected individuals intolerant of efavirenz or ritonavir-boosted protease inhibitors
2008-000604-88Phase 4Terminated
- Sponsor
- St Stephen's AIDS Trust
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of darunavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by St Stephen's AIDS Trust. Primary endpoint: Improvement of NNRTI/PI-associated toxicity after 4 weeks of therapy with ritonavir-boosted darunavir. Started Feb 2008; status: terminated.
02
Drugs
darunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2008-000604-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000604-88.